IP Library › Granted Patent US 7,732,417
Granted Patent B2
US 7,732,417 · App. 09/858,862 · Granted Jun 8, 2010

Methods and compositions for RNA interference using recombinant Dicer and Argonaut

Assignee: Cold Spring Harbor Laboratory
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,732,417
App. No.
09/858,862
Granted
Jun 8, 2010
Kind
B2
Abstract

The present invention provides methods for attenuating gene expression in a cell using gene-targeted double stranded RNA (dsRNA). The dsRNA contains a nucleotide sequence that hybridizes under physiologic conditions of the cell to the nucleotide sequence of at least a portion of the gene to be inhibited (the “target” gene).

Claims (12)

1. A method for attenuating expression of a target gene in a non-embryonic mammalian cell in culture, comprising introducing into the cell by transfection a double stranded RNA (dsRNA) in an amount sufficient to attenuate expression of the target gene, wherein the dsRNA is about 22 nucleotides in length and complementary across its length to a nucleotide sequences of the target gene and does not activate protein kinase RNA-activated (PKR) sequence-independent response, and wherein the cell is engineered with (i) a recombinant gene encoding a Dicer activity, (ii) a recombinant gene encoding an Argonaut activity, or (iii) both.

2. The method of claim 1 , wherein the recombinant gene encodes a protein which includes an amino acid sequence at least 95% identical to SEQ ID NO: 2, 4 or 5.

3. The method of claim 1 , wherein the recombinant gene includes a coding sequence that hybridizes to SEQ ID NO: 1 or 3 under a wash condition of 2×SSC at 22° C.

4. The method of claim 1 , wherein the target gene is an endogenous gene of the cell.

5. The method of claim 1 , wherein the target gene is an heterologous gene relative to the genome of the cell.

6. The method of claim 1 , wherein expression of the target gene is attenuated by at least 10 fold.

7. The method of claim 1 , wherein the transfection is mediated by calcium precipitating agents.

8. The method of claim 1 , wherein the transfection is mediated by lipid carrier agents.

9. The method of claim 1 , wherein the dsRNA is produced by a vector.

10. The method of claim 5 , wherein the target gene is a pathogen gene.

11. The method of claim 1 , wherein the cell is a primate cell.

12. The method of claim 1 , wherein the cell is a human cell.

Assignments (5)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 17, 2008
From: BEACH, DAVID H.
To: GENETICA INC.
Reel/Frame 021250/0929 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 17, 2008
From: GENETICA INCORPORATED
To: COLD SPRING HARBOR LABORATORY
Reel/Frame 021251/0021 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 17, 2008
From: BERNSTEIN, EMILY; HANNON, GREGORY J.
To: COLD SPRING HARBOR LABORATORY
Reel/Frame 021251/0239 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 17, 2008
From: CAUDY, AMY
To: COLD SPRING HARBOR LABORATORY
Reel/Frame 021251/0651 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 17, 2004
From: HAMMOND, SCOTT (FOR GENETICA, INC.)
To: COLD SPRING HABOR LABORATORY
Reel/Frame 015474/0269 →
Continuity (4)
Continuation In Part PCTUS010843500 · Mar 16, 2001
Provisional Application 6018973900 · Mar 16, 2000
Provisional Application 6024309700 · Oct 24, 2000
Related Publication 20040018999A1 · Jan 29, 2004